Antibody Testing Opportunity CBL PATH Inc launched COVID-19 antibody testing in April 2020, indicating experience with infectious disease diagnostics and a potential extension into antibody-based screening partnerships or broader serology services for healthcare providers and employers.

Molecular Diagnostics Strength Existing molecular PCR testing capability suggests potential for bundled molecular pathology services, laboratory automation collaborations, and scalable testing programs for clinics and hospital networks seeking end-to-end diagnostic solutions.

Mid-Sized lab Focus With 51-200 employees, CBL PATH sits in a mid-sized lab segment that can benefit from partnerships with larger reference labs for volume referrals, co-marketing arrangements, and technology-enabled workflow integrations.

Tech Stack Readiness Utilizes cloud and workflow tools (AWS, Smartsheet, OneTrust, Box, DocuSign) indicating openness to digital transformation, data interoperability, and enterprise-grade compliance—opportunities to offer LIMS integrations, data security enhancements, and automation services.

Revenue potential Reported revenue range of 1M to 10M signals target segments for mid-market healthcare labs and opportunities to propose scalable pricing models, managed services, or bundled offerings to grow testing throughput and client footprint.